Veritas Pharma Signs IP Agreement with UK’s First Medicinal Cannabis Investment Fund

0
247

VANCOUVER, British Columbia, July 17, 2018 (GLOBE NEWSWIRE) — Veritas Pharma Inc.(CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), (“Veritas” or the “Company”) is pleased to announce that it has signed an Intellectual Property Sharing Agreement (“Joint IP”) with Sativa Investments PLC (“Sativa”) (NEX:SATI), UK’s first medicinal cannabis investment fund. Veritas through its subsidiary company, Cannevert Therapeutics Ltd., will apply its pharmacological methods on cannabis strain lead selection to assist Sativa’s application to the UK Home Office Drugs Licensing and Compliance Unit for a medicinal cannabis growing license. As previously announced on May 21, 2018, Sativa subscribed on a non-brokered private placement basis to Common Shares of Veritas for gross proceeds to the Company of C$ 0.2 million. Veritas Pharma Signs IP Agreement with UK’s First Medicinal Cannabis Investment Fund

thumbnail courtesy of nasdaq.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here